With more-advanced renal failure, phosphate binders become necessary to maintain phosphate balance and to prevent hyperphosphatemia. Because of toxicity, aluminum-containing phosphate binders are ...

Background: Aluminium-containing phosphate binders have long been used for treatment of hyperphosphatemia in dialysis patients. Their safety became controversial in the early 1980's after reports ...

Extensive coronary artery calcification (CAC) is common in people on hemodialysis. Sevelamer, a phosphate binder that does not contain calcium, is associated with slower progression of CAC than ...

Hyperphosphatemia is linked to increased mortality risk. Dialysis patients often face a high daily pill burden, with phosphate binders making up about 50% of the total. Nonadherence to phosphate ...